APA (7th ed.) Citation

AM, G., S, J., YY, H., J, Y., T, W., G, O., . . . JB, V. (2025). Real-world use of adjuvant nivolumab among patients with esophageal and gastroesophageal junction cancer at a large integrated health system. JTCVS open, 28, 632. https://doi.org/10.1016/j.xjon.2025.10.003

Chicago Style (17th ed.) Citation

AM, Gochi, Jeffs S, Hung YY, Yang J, Wang T, Okano G, Rosenblatt L, Villacorta R, and Velotta JB. "Real-world Use of Adjuvant Nivolumab Among Patients with Esophageal and Gastroesophageal Junction Cancer at a Large Integrated Health System." JTCVS Open 28 (2025): 632. https://doi.org/10.1016/j.xjon.2025.10.003.

MLA (9th ed.) Citation

AM, Gochi, et al. "Real-world Use of Adjuvant Nivolumab Among Patients with Esophageal and Gastroesophageal Junction Cancer at a Large Integrated Health System." JTCVS Open, vol. 28, 2025, p. 632, https://doi.org/10.1016/j.xjon.2025.10.003.